Business Description
Roivant Sciences Ltd
ISIN : BMG762791017
Share Class Description:
FRA:87S: Ordinary SharesDescription
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 14.98 | |||||
| Equity-to-Asset | 0.84 | |||||
| Debt-to-Equity | 0.07 | |||||
| Debt-to-EBITDA | 0.08 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 12.21 | |||||
| Beneish M-Score | -0.15 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 62.4 | |||||
| 3-Year EPS without NRI Growth Rate | -15.6 | |||||
| 3-Year FCF Growth Rate | -4.2 | |||||
| 3-Year Book Growth Rate | 41.3 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 47.15 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 53.49 | |||||
| 9-Day RSI | 53.59 | |||||
| 14-Day RSI | 53.21 | |||||
| 6-1 Month Momentum % | 13.87 | |||||
| 12-1 Month Momentum % | 49.22 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 27.91 | |||||
| Quick Ratio | 27.75 | |||||
| Cash Ratio | 26.41 | |||||
| Days Inventory | 398.34 | |||||
| Days Sales Outstanding | 121.55 | |||||
| Days Payable | 1002.07 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -5.6 | |||||
| Shareholder Yield % | 5.35 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 90.32 | |||||
| Operating Margin % | -661.14 | |||||
| Net Margin % | 2991.76 | |||||
| FCF Margin % | -448.5 | |||||
| ROE % | 122.36 | |||||
| ROA % | 93.84 | |||||
| ROIC % | -160.34 | |||||
| 3-Year ROIIC % | -1499.39 | |||||
| ROC (Joel Greenblatt) % | 6533 | |||||
| ROCE % | 97.7 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 2.09 | |||||
| PS Ratio | 59.09 | |||||
| PB Ratio | 1.58 | |||||
| Price-to-Tangible-Book | 1.62 | |||||
| EV-to-EBIT | 0.71 | |||||
| EV-to-EBITDA | 0.7 | |||||
| EV-to-Revenue | 20.9 | |||||
| EV-to-Forward-Revenue | 9.74 | |||||
| EV-to-FCF | -4.66 | |||||
| Price-to-Net-Current-Asset-Value | 1.74 | |||||
| Price-to-Net-Cash | 1.86 | |||||
| Earnings Yield (Greenblatt) % | 140.85 | |||||
| FCF Yield % | -8.25 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Roivant Sciences Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 146.655 | ||
| EPS (TTM) (€) | 5.091 | ||
| Beta | 2.05 | ||
| Volatility % | 35.09 | ||
| 14-Day RSI | 53.21 | ||
| 14-Day ATR (€) | 0.255701 | ||
| 20-Day SMA (€) | 10.38675 | ||
| 12-1 Month Momentum % | 49.22 | ||
| 52-Week Range (€) | 7.55 - 11.485 | ||
| Shares Outstanding (Mil) | 739.52 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Roivant Sciences Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Roivant Sciences Ltd Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Roivant Sciences Ltd Frequently Asked Questions
What is Roivant Sciences Ltd(FRA:87S)'s stock price today?
The current price of FRA:87S is €10.53. The 52 week high of FRA:87S is €11.49 and 52 week low is €7.55.
When is next earnings date of Roivant Sciences Ltd(FRA:87S)?
The next earnings date of Roivant Sciences Ltd(FRA:87S) is 2024-11-12.
Does Roivant Sciences Ltd(FRA:87S) pay dividends? If so, how much?
Roivant Sciences Ltd(FRA:87S) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers